结论：国人非遗传性肾透明细胞癌中存在VHL基因的突变，且与患者年龄，肿瘤分期、分级无相关性。
The mutations of VHL gene were irrespective of the age and pathological grade and stage of patients.
现有证据显示所有的羟乙基淀粉产品在所有的患者人群中都会增加急性肾损伤和肾脏替代治疗的风险，且羟乙基淀粉溶液的安全用量还没有被确定。
The current evidence suggests that all HES products increase the risk in AKI and RRT in all patient populations and a safe volume of any HES solution has yet to be determined.
应用推荐